CDEK
← All organizations

Roivant Sciences, Inc.

For profitContributed to NMEWebsite ↗

Also known as: ALYVANT | DERMAVANT SCI | Dermavant Sciences, Chief Medical Officer | Dermavant Sciences GmbH | Dermavant Sciences, Inc. | Pulmovant, Inc. | ROIVANT | Spirovant Sciences, Inc. | Sumitovant Biopharma, Inc. | Telavant, Inc.

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Dec 1, 2015

First marketed drug

Mar 3, 2017

First NDA

May 23, 2022

Last known activity

Jun 10, 2025

Acquired by Sumitomo → Sumitomo Dainippon on Apr 2, 2023

Timeline

2000s

  1. Jan 1, 2005

    Sumitomo Dainippon— Now

2010s

  1. May 1, 2014

    Roivant Sciences, Inc.— Founded

  2. Mar 3, 2017

    desmopressin— Marketing Organization

  3. Aug 9, 2017

    Karos Pharmaceuticals— Acquired

  4. Jan 1, 2018

    Respivant Sciences Inc.— Acquired

  5. Dec 21, 2018

    Kinevant Sciences GmbH— Acquired

2020s

  1. Feb 25, 2021

    Silicon Therapeutics— Acquired

  2. May 23, 2022

    tapinarof— NDA Organization

  3. May 23, 2022

    tapinarof— NDA Secondary Org

  4. Apr 2, 2023

    Sumitomo— Acquired By

Drugs by trial phase (18 distinct, 31 trials)

Phase 4 (1 own, 0 via acquisition)

Phase 3 (1 own, 0 via acquisition)

Indications

Studied for

Marketed drugs (2)

Subsidiaries (4 direct, 4 total across the full acquisition tree)

Recent trials (40)

Details

Founded
Basel, CH May 1, 2014
First NDA
May 23, 2022
Last known activity
Jun 10, 2025